NEGR1 (Neuronal Growth Regulator 1) encodes a GPI-anchored cell adhesion molecule¹¹ GPI-anchored cell adhesion molecule
Glycosylphosphatidylinositol — a lipid anchor that attaches proteins to the outer surface of cell membranes belonging to the IgLON family. It is strongly expressed in the hypothalamus — the brain region that governs hunger, satiety, and energy balance. The rs2815752 variant sits upstream of NEGR1 and alters its expression, making it one of the first obesity-associated genes identified by genome-wide association studies that pointed to a neuronal, rather than metabolic, mechanism for weight gain.

The Mechanism

NEGR1 promotes neurite outgrowth, synapse formation, and cell-cell adhesion in hypothalamic neurons, particularly in the arcuate nucleus²² arcuate nucleus
The arcuate nucleus contains hunger-promoting (AgRP/NPY) and satiety-promoting (POMC) neurons that integrate signals from hormones like leptin and ghrelin and ventromedial hypothalamus. It accumulates at GABAergic inhibitory synapses and promotes clustering of GAD65³³ GAD65
Glutamic acid decarboxylase 65 — the enzyme that synthesizes GABA, the main inhibitory neurotransmitter at synaptic membranes. When NEGR1 expression is reduced — as occurs with the A risk allele — hypothalamic appetite circuits are disrupted: the GABAergic synaptic architecture weakens, and the brain's ability to regulate food intake diminishes.

A linked 45-kb deletion polymorphism upstream of NEGR1 removes several conserved regulatory elements, likely explaining how the common risk haplotype reduces NEGR1 expression. ⁴⁴ Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet, 2009

The Evidence

The NEGR1 locus was identified in the landmark GIANT consortium GWAS⁵⁵ GIANT consortium GWAS
Willer et al. Meta-analysis of 15 GWAS for BMI (n>32,000) with replication in 14 cohorts (n>59,000). Nat Genet, 2009 as one of six new BMI loci, with the A allele increasing BMI by 0.10 kg/m² per copy (P = 6.0 x 10^-8, combined n = 83,499). The largest BMI meta-analysis to date (339,224 individuals⁶⁶ 339,224 individuals
Locke et al. Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015) confirmed NEGR1 among 97 genome-wide significant loci and highlighted its central nervous system expression pattern.

Mouse studies validate the human genetics. NEGR1-knockout mice show reduced body mass (8-13%)⁷⁷ reduced body mass (8-13%)
Lee et al. Functional inactivation of the GWAS obesity gene NEGR1 in mice causes a body mass phenotype. PLOS ONE, 2012, decreased food intake, and reduced lean mass — confirming NEGR1's role in appetite and body composition. In rats, decreased hypothalamic NEGR1 expression⁸⁸ decreased hypothalamic NEGR1 expression
Boender et al. The obesity-associated gene Negr1 regulates aspects of energy balance in rat hypothalamic areas. Physiol Genomics, 2014 directly increases body weight and food intake, particularly affecting carbohydrate preference.

In a human dietary study of 26,107 participants, the A risk allele was associated with lower fat intake but higher carbohydrate and fiber intake⁹⁹ A risk allele was associated with lower fat intake but higher carbohydrate and fiber intake
Rukh et al. Genetic susceptibility to obesity and diet intakes in the Malmö Diet and Cancer Study. Genes Nutr, 2013, suggesting NEGR1 influences not just how much we eat but what we prefer to eat.

Practical Actions

Because the A allele is extremely common (carried by 86% of Europeans and over 99% of East Asians as at least one copy), this is not a rare high-impact variant — it is a common, moderate-effect contributor to obesity susceptibility. The practical value lies in understanding your position on the appetite regulation spectrum.

Carriers of two A alleles should focus on structured meal timing and protein-forward meals to support satiety signaling that their hypothalamic wiring handles less efficiently. Monitoring waist circumference rather than just body weight captures the metabolic risk more accurately.

Interactions

NEGR1 contributes to a polygenic obesity risk profile alongside FTO (rs9939609) and MC4R (rs17782313). While each variant has a modest individual effect, carrying risk alleles at multiple loci has a cumulative impact on BMI. A combined FTO + NEGR1 risk genotype may warrant more structured appetite management strategies than either alone.

NEGR1 is also a cross-trait hit for major depressive disorder, with integrative genomic analysis¹⁰¹⁰ integrative genomic analysis
Li et al. Integrating GWAS and eQTL data identifies NEGR1 as a causal risk gene of major depression. J Affect Disord, 2020 identifying it as a causal MDD risk gene. The shared neurodevelopmental mechanism — disrupted synaptic connectivity in hypothalamic and limbic circuits — may explain why obesity and depression so often co-occur. Carriers of the A allele at rs2815752 who also carry depression-associated variants may experience compounded effects on both appetite regulation and mood.

Deep inside every primordial follicle, an arrested oocyte faces a biological paradox: it must preserve its genetic integrity across potentially decades before fertilisation, while its genome is under constant threat from parasitic DNA elements called transposable elements¹¹ transposable elements
mobile genetic sequences that can copy themselves and insert elsewhere in the genome, causing mutations if unchecked. The piRNA pathway — named for the PIWI-interacting RNAs that guide it — is the germline's primary defence against this threat. PIWIL1 is one of four human PIWI proteins, and it is expressed in meiotic oocytes in primordial follicles, where it helps silence endogenous retroviruses and other transposons that would otherwise compromise egg quality and genome stability.

The rs28416520 variant sits in a CpG-rich regulatory region of the PIWIL1 promoter. The A allele modifies local CpG methylation patterns, altering PIWIL1 transcription in germ cells. Critically, its effect on ovarian ageing follows a recessive inheritance pattern²² recessive inheritance pattern
recessive: two copies of the risk allele are required to produce the full effect; one copy alone has little impact.

The Mechanism

PIWIL1 belongs to the Argonaute superfamily of RNA-guided silencing proteins. In oocytes, it binds piRNAs — a class of small non-coding RNAs (23–29 nucleotides) derived from transposon sequences — and uses these guides to recognise and cleave complementary transposon transcripts. In golden hamsters, which express PIWIL1 throughout oogenesis analogously to humans, disruption of PIWIL1 causes oocyte dysfunction through transposon de-silencing and widespread transcriptomic dysregulation, leading to embryonic arrest³³ disruption of PIWIL1 causes oocyte dysfunction through transposon de-silencing and widespread transcriptomic dysregulation, leading to embryonic arrest
Lim et al. 2021, Nature Cell Biology — PIWIL1-null female hamsters are sterile due to piRNA-pathway failure in oocytes. In humans, PIWIL1 nuclear foci are observed specifically in meiotic oocytes within primordial follicles.

The rs28416520 promoter variant likely reduces PIWIL1 expression in a dosage-dependent manner: one A allele can be compensated by the remaining G allele, but AA homozygosity results in insufficient PIWIL1 activity to maintain full transposon surveillance. Over the long dormant period of primordial follicle maintenance, progressive transposon-mediated DNA damage may accelerate follicle loss and bring forward the timing of menopause.

The Evidence

The primary evidence comes from a landmark genome-wide association study by Ruth et al. 2021⁴⁴ genome-wide association study by Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393–397 examining approximately 200,000 women of European ancestry. This study identified 290 genetic determinants of ovarian ageing, measured as variation in age at natural menopause (ANM). rs28416520 at the PIWIL1 locus was among the variants that showed significant departure from the additive allelic model, exhibiting instead a recessive pattern — meaning AA homozygotes showed a substantially larger effect on menopause timing than would be predicted if the effects simply added up per allele. The study also demonstrated that experimental manipulation of piRNA-pathway genes highlighted by this GWAS increases fertility and extends reproductive life in mice, directly validating the biological relevance of this pathway to ovarian reserve.

A promoter functional study of rs28416520⁵⁵ promoter functional study of rs28416520
Zhang et al. 2020, assessing CpG-region SNPs in the PIWIL1 promoter in a Chinese gastric cancer cohort confirms that this SNP alters methylation-sensitive regulatory activity in the PIWIL1 promoter, establishing that it has measurable effects on PIWIL1 transcription.

A comprehensive study of inherited piRNA pathway defects⁶⁶ comprehensive study of inherited piRNA pathway defects
Wyrwoll et al. 2024, Nature Communications — 39 infertile men carrying biallelic variants in 14 piRNA pathway genes including PIWIL1 demonstrates that PIWIL1 loss-of-function follows an autosomal recessive pattern in humans and causes germline transposon de-repression with consequent germ cell failure. This human genetic data is entirely consistent with the recessive model seen for rs28416520 in the ovarian ageing GWAS.

Practical Actions

For the roughly 14% of women who carry two A alleles, the implications are most relevant to reproductive planning. The recessive architecture means GA heterozygotes (approximately 46% of women) are not meaningfully affected — only AA homozygotes carry the elevated risk. AA women may experience earlier decline in ovarian reserve than the population average, warranting earlier baseline measurement of anti-Müllerian hormone (AMH) and antral follicle count if family planning is a consideration.

Because the mechanism involves piRNA-pathway surveillance of transposon activity in oocytes, and because oxidative DNA damage is known to accelerate follicle depletion generally, strategies to protect oocyte genome integrity — particularly avoiding genotoxic exposures such as tobacco smoke — are especially relevant for AA homozygotes.

Interactions

PIWIL1 functions within a larger piRNA biogenesis network that includes PIWIL2, PIWIL3, and PIWIL4, plus scaffold proteins (TDRD1, TDRD9, HENMT1, MAEL) and RNA-modifying enzymes. Women carrying variants in multiple piRNA pathway genes may have compounded effects on piRNA biogenesis. The ovarian ageing GWAS (Ruth et al. 2021) also implicated other DNA damage response loci, including rs10183486 (TLK1) and rs16991615 (MCM8), that may act through convergent pathways with PIWIL1 to influence the cumulative rate of follicle depletion. A formal compound analysis of PIWIL1 + TLK1 genotypes has not been published but is biologically plausible given both genes act to protect oocyte DNA integrity.

The immune system is not a passive bystander in endometriosis — it is an active participant. Interleukin-1 alpha¹¹ Interleukin-1 alpha
IL-1α: a pro-inflammatory cytokine produced chiefly by macrophages and monocytes; signals through the IL-1 receptor to activate NF-κB and trigger downstream inflammatory cascades is one of the most consistently elevated cytokines in the peritoneal fluid of women with endometriosis. The gene encoding IL-1α, IL1A, resides on chromosome 2q14.1 and harbors a cluster of common variants that have emerged from multiple genetic association studies as replicated susceptibility factors for the disease. Among these, rs2856836 — located in the 3' untranslated region of the IL1A transcript — is one of eight IL1A locus SNPs shown to replicate across both European and Japanese populations.

The Mechanism

rs2856836 is a 3' UTR variant²² 3' UTR variant
variants in the 3' untranslated region can alter mRNA stability, translational efficiency, or microRNA binding sites, affecting how much protein the gene ultimately produces. It does not change the IL-1α amino acid sequence. On the plus (forward) strand the reference allele is A and the alternate allele is G; because IL1A is transcribed from the minus strand, published papers commonly describe this as a T/C variant in coding-strand notation (T=reference, C=risk). The G allele (plus strand) sits at position chr2:112,774,506 (GRCh38), 561 nucleotides into the 3' UTR of transcript NM_000575.5.

The functional consequence of this specific 3'UTR change has not been experimentally characterised in isolation. The broader IL1A endometriosis risk locus, however, has been functionally mapped in detail: expression quantitative trait locus (eQTL) analysis across ten tissue types³³ expression quantitative trait locus (eQTL) analysis across ten tissue types
Ochoa et al. 2025, Adv Sci; PMC12591210 shows that risk variants at the IL1A locus are associated with decreased IL1A expression, and that M2 peritoneal macrophages — the cell type that lines the peritoneal cavity and governs immune tolerance of ectopic endometrial tissue — are the primary germline risk mediators at this locus. The IL1A/IL1B cytokines scored the highest correlation with endometriosis risk across myeloid subgroups (Spearman r=0.59). In the endometriosis-affected peritoneal environment, dysregulated IL-1 signaling may impair macrophage-mediated clearance of refluxed endometrial cells — the critical gatekeeping step that, when disrupted, allows retrograde tissue to implant and establish ectopic lesions.

The Evidence

The first signal at the IL1A locus came from a genome-wide association meta-analysis in Japanese women⁴⁴ genome-wide association meta-analysis in Japanese women
Adachi et al. 2010, J Hum Genet; 696 cases + 825 controls in which four of the five top-ranked SNPs (P<10⁻⁵) clustered around IL1A, identifying it as a functional candidate gene. A follow-up study⁵⁵ follow-up study
Hata et al. 2013, J Hum Genet of 901 Japanese cases and controls confirmed rs2856836 as one of four significantly associated IL1A variants (P=0.0014), alongside the missense variant rs17561 (Ala114Ser, OR=1.91 in validation). Cross-ethnic replication came from a meta-analysis of 3,908 cases and 8,568 controls⁶⁶ meta-analysis of 3,908 cases and 8,568 controls
Sapkota et al. 2015, Hum Reprod; PMC4262465 spanning Australian, British, and Japanese cohorts, where all eight IL1A SNPs replicated at P<0.014 with concordant effect directions. For rs2856836 specifically, the meta-analysis yielded OR=1.09 (95% CI 1.02–1.16, P=7.15×10⁻³) across all endometriosis, and OR=1.12 (95% CI 1.04–1.22, P=4.29×10⁻³) for moderate-to-severe (grade B) disease.

A smaller population-specific case-control study in Iranian women⁷⁷ Iranian women
Badie et al. 2020, Gynecol Endocrinol; 105 cases, 102 controls found a stronger effect for the G allele (coding-strand C) — OR=2.2 (95% CI 1.4–3.6, P=0.001) — with TC and CC genotypes independently significant (OR=3.1 and OR=2.3 respectively). This larger per-allele estimate likely reflects the smaller study size and possible founder effects in the Iranian population rather than a qualitatively different genetic architecture.

No ClinVar classification exists for rs2856836. The association signal is consistent with a moderate-evidence risk factor: replicated across multiple ethnic groups with clear dose-response, plausible biological mechanism, but short of genome-wide significance and lacking direct functional characterisation of this specific variant.

Practical Actions

The central implication of carrying one or two copies of the G allele is a modestly elevated inflammatory predisposition toward endometriosis. The individual risk increment per G allele is small in absolute terms (OR ~1.09–1.12 per allele in the large meta-analysis), and this variant should be interpreted in the context of the broader IL1A locus and other endometriosis risk SNPs. Women carrying the G allele who experience dysmenorrhea, cyclic pelvic pain, deep dyspareunia, or unexplained infertility should not normalize these symptoms — earlier gynecological evaluation shortens the diagnostic delay that averages 7–10 years.

The inflammatory basis of this association suggests that strategies targeting pelvic inflammation may be particularly relevant: NSAIDs, which block prostaglandin synthesis downstream of IL-1 signaling, are first-line for endometriosis-associated pain. No supplement or dietary intervention has been shown to specifically modulate IL1A expression or activity in peritoneal macrophages. The management decision — including hormonal therapy, surgical evaluation, or fertility preservation — rests with a gynecologist.

Interactions

rs2856836 is in linkage disequilibrium⁸⁸ linkage disequilibrium
LD: the tendency of nearby variants to be inherited together on the same chromosomal segment with the other seven IL1A locus SNPs studied by Sapkota et al. (2015), including the genome-wide significant regulatory variant rs6542095 (OR=1.21 for moderate-to-severe endometriosis) and the missense variant rs17561 (Ala114Ser). These SNPs reside within a ~8 kb stretch of the IL1A gene. Carriers of risk alleles at multiple IL1A locus SNPs may accumulate greater susceptibility through haplotype effects, though the independent contribution of each variant has not been formally dissected. The functional eQTL evidence points to the entire locus region modulating IL1A expression in M2 peritoneal macrophages — the single causal variant within this cluster has not been definitively identified.

Every cell in your body is under constant immunological inspection. The key checkpoint is MHC class I antigen presentation¹¹ MHC class I antigen presentation
a process by which cells display short peptide fragments on their surface for surveillance by CD8+ cytotoxic T cells — abnormal peptides trigger immune attack, and the quality of that display depends critically on an upstream editing step: peptide trimming by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)²² ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)
an enzyme that clips peptides to exactly the right length (8-10 amino acids) before they can bind MHC class I molecules and reach the cell surface.

The rs30187 K528R variant changes a single amino acid in ERAP1's hinge region — and that single change fundamentally alters the enzyme's activity. The result is a miscalibrated peptide-trimming machine that shifts what your immune system sees and, in specific HLA backgrounds, increases the risk of two well-characterized autoimmune conditions: ankylosing spondylitis and psoriasis.

The Mechanism

ERAP1 acts as a molecular ruler³³ molecular ruler
the enzyme has a substrate-binding pocket that physically measures peptide length; when the peptide fits optimally, ERAP1 clips one amino acid and releases the peptide for loading onto MHC class I molecules. The enzyme cycles between an open (inactive) and closed (active) conformation. Lys528 (the common C-allele residue) sits at the hinge region that governs this conformational switch — it facilitates efficient transition to the closed, catalytically active state.

The K528R substitution (T allele) replaces lysine with arginine at position 528. Despite the chemical similarity, this change alters the kinetics of the open-to-closed transition, producing a hypofunctional enzyme⁴⁴ hypofunctional enzyme
an ERAP1 variant that trims peptides more slowly and incompletely than the common form. In biochemical assays, the K528R variant stalls at the 11-mer peptide stage — it can begin trimming but cannot efficiently complete the process to generate optimal 8-9 mer peptides. This means the T-allele ERAP1 produces a different peptide repertoire than the common enzyme: more long peptides that cannot bind MHC class I, and fewer optimal-length peptides that can.

The clinical consequence of this altered peptide landscape depends entirely on which HLA class I molecules are present in a given individual. This is why rs30187 exhibits strict epistasis⁵⁵ epistasis
a genetic interaction where the effect of one variant is entirely conditional on the genotype at a second locus with both HLA-B27 (in ankylosing spondylitis) and HLA-C*06:02 (in psoriasis).

The Evidence

Ankylosing Spondylitis: The foundational paper — a landmark GWAS meta-analysis published in Nature Genetics in 2011⁶⁶ landmark GWAS meta-analysis published in Nature Genetics in 2011
Evans et al., WTCCC2 consortium, 3,023 AS cases and 8,779 controls with replication in 2,871 cases and 9,087 controls — established that ERAP1 rs30187 is the single most functionally important coding variant in ERAP1 for AS susceptibility. The association follows strict HLA-B27 epistasis: ERAP1 variants were significantly associated with AS only in HLA-B27–positive individuals (combined P=7.3×10⁻⁶ for interaction), with no detectable association in HLA-B27–negative patients. HLA-B27–positive individuals homozygous for the protective C allele at rs30187 had approximately 3-4 times lower AS risk than HLA-B27–positive individuals carrying T-allele risk genotypes.

An updated meta-analysis incorporating 19,902 AS patients and 39,750 controls⁷⁷ updated meta-analysis incorporating 19,902 AS patients and 39,750 controls
Tian et al. 2015 confirmed the overall association (OR=1.255, 95% CI: 1.147-1.373, P=8.0×10⁻⁸), with the effect strongest in European populations (OR=1.283, 95% CI: 1.237-1.331, P<1.0×10⁻⁹).

Psoriasis: In psoriasis, rs30187 shows a more complex and bidirectional epistasis with HLA-C*06:02. A Polish cohort study⁸⁸ Polish cohort study
Szczerkowska-Dobosz et al. 2018, examining ERAP1/ERAP2 haplotypes stratified by HLA-C*06:02 status and disease onset showed that the T allele increases psoriasis risk in HLA-C*06:02 carriers (particularly late-onset disease) but is protective when HLA-C*06:02 is absent. This paradoxical direction-switching is a hallmark of epistatic interactions and underscores that the biological effect of K528R is entirely context-dependent.

A meta-analysis of nine case-control studies⁹⁹ meta-analysis of nine case-control studies
Wu et al. 2021, 4,858 psoriasis cases and 10,542 healthy controls confirmed the overall positive association (T vs C: OR=1.23, 95% CI: 1.15-1.32, P<0.00001), averaging across HLA backgrounds.

Functional validation: The mechanistic basis was confirmed by a functional study of naturally occurring ERAP1 haplotypes¹⁰¹⁰ functional study of naturally occurring ERAP1 haplotypes
Evnouchidou et al. 2013, PMC3785127 — comparative biochemical characterization of 10 ERAP1 haplotypes using diverse peptide substrates. The K528R variant consistently produced a hypofunctional enzyme across multiple substrates, generating incomplete trimming products rather than optimal 8-9 mer peptides. This directly demonstrates how the variant reshapes the peptide repertoire available for MHC class I loading.

Practical Implications

The T allele at rs30187 reduces ERAP1's peptide-editing efficiency. On its own, this is unlikely to cause disease — the altered peptide repertoire only becomes clinically meaningful when a specific HLA class I allele is present to present those aberrant or deficient peptides to the immune system.

If you carry the T allele and also carry HLA-B27 (not yet tested by GeneOps), your risk of ankylosing spondylitis is substantially elevated above the HLA-B27-only baseline. If you carry the T allele and also carry HLA-C*06:02 (check rs12191877), your risk of psoriasis is increased compared to HLA-C*06:02 carriers with the CC genotype.

Ankylosing spondylitis is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. It typically begins in young adulthood with morning back stiffness that improves with activity. Early diagnosis and appropriate treatment (NSAIDs, biologics targeting TNF or IL-17/IL-23) can prevent irreversible spinal fusion and maintain mobility.

Interactions

ERAP1 rs30187 × HLA-B27: Ankylosing Spondylitis Epistasis

The epistatic interaction between rs30187 and HLA-B27 in AS is one of the strongest documented gene-gene interactions in complex disease genetics. HLA-B27 presents a peptide repertoire that depends heavily on ERAP1's trimming output. The K528R variant changes which peptides are available, altering self-peptide presentation in a way that — in HLA-B27 carriers — tips the balance toward autoreactive immune activation. This interaction argues that the pathogenic mechanism of HLA-B27 in AS is fundamentally peptide-presentation-dependent.

This interaction is a candidate for compound action documentation. The relevant genotypes are: - rs30187 CT or TT (ERAP1 K528R risk allele present) combined with HLA-B27 positive status Combined recommendation: heightened AS surveillance, early rheumatological assessment for inflammatory back pain, and discussion of anti-inflammatory prophylaxis.

ERAP1 rs30187 × HLA-C*06:02 (rs12191877): Psoriasis Epistasis

The bidirectional epistasis with HLA-C*06:02 mirrors the psoriasis mechanism of the sibling variant rs27524. Where rs27524 alters ERAP1 expression levels, rs30187 alters ERAP1 catalytic efficiency — both ultimately modify the density and identity of peptides presented by HLA-C*06:02 on melanocytes. In HLA-C*06:02 carriers, the T allele's hypofunctional enzyme generates a different ADAMTSL5 peptide profile, contributing to psoriatic autoimmunity.

ERAP1 rs30187 × ERAP1 rs27524: Same-gene compound effect

rs30187 (K528R, coding missense) and rs27524 (intronic eQTL) affect ERAP1 through orthogonal mechanisms — one changes the enzyme's activity, the other changes its expression level. They co-occur on different haplotypes. The naturally occurring ERAP1 haplotype system (Hap1-Hap10) captures both variants together. Individuals inheriting risk haplotypes at both positions will have both more ERAP1 protein and less efficient ERAP1 protein — creating a complex net effect that varies by haplotype combination.

Von Willebrand factor (VWF) is the molecular glue of hemostasis — a large plasma protein that tethers platelets to damaged blood vessel walls and serves as the carrier and protector of coagulation Factor VIII (FVIII). The rs33978901 variant introduces a single amino acid change, replacing arginine with glutamine at position 924¹¹ replacing arginine with glutamine at position 924
p.Arg924Gln, encoded by c.2771G>A in the VWF coding sequence; the gene lies on the minus strand, so the plus-strand T allele corresponds to the coding-strand A allele. Unlike the dramatic pathogenic mutations in classical von Willebrand disease, this variant acts as a subtle modifier: in most carriers it causes no clinical problem, but in the wrong context — especially blood group O — it can push already-low VWF levels into a range that warrants medical attention.

The Mechanism

In vitro expression studies of recombinant p.R924Q VWF²² In vitro expression studies of recombinant p.R924Q VWF
Hickson et al. tested the variant protein in cell culture: no effect on VWF secretion, multimer structure, or FVIII binding was found showed no detectable functional defect. This means R924Q likely does not impair VWF protein directly but instead travels on a haplotype — a block of inherited variants³³ haplotype — a block of inherited variants
A haplotype is a set of alleles inherited together as a unit; the R924Q allele appears to tag a chromosomal background that is associated with reduced VWF production associated with lower VWF output. The biological mechanism is therefore quantitative (reduced VWF levels) rather than qualitative (abnormal protein structure or function).

The ABO blood group⁴⁴ ABO blood group
Encoded by the ABO gene on chromosome 9; the H antigen added to VWF by non-O blood groups increases its half-life and plasma concentration by protecting it from clearance independently controls VWF levels: blood group O individuals have VWF concentrations 25-35% lower⁵⁵ 25-35% lower
Consistently documented across multiple population studies; the mechanism involves reduced glycosylation protecting VWF from ADAMTS13 cleavage and macrophage clearance than non-O individuals. When R924Q-associated reduced production overlaps with blood group O's reduced half-life, the combined effect explains up to 35% of VWF variance⁶⁶ the combined effect explains up to 35% of VWF variance
Versus ~10% for the variant alone in controls not stratified by blood group — a clinically meaningful amplification.

The Evidence

The definitive study is Hickson et al. 2010⁷⁷ Hickson et al. 2010
Journal of Thrombosis and Haemostasis; 1,115 healthy controls and 148 von Willebrand disease index cases genotyped for c.2771G>A. Among 148 VWD index cases, the variant appeared in six; five of those six carried at least one additional VWF pathogenic mutation, indicating R924Q rarely causes VWD on its own but frequently appears as a co-factor. Among healthy controls, 35 heterozygous carriers were identified. Crucially, variance in VWF and FVIII levels attributable to the variant jumped from 10% overall to 35% in blood group O carriers — demonstrating strong epistatic amplification.

ClinVar (VCV000100240) reflects this nuanced picture: across 11 contributing submissions, classifications range from benign to uncertain significance, with no pathogenic calls. Major clinical laboratories (Mayo Clinic, ARUP, Quest Diagnostics) classify it as benign or likely benign in isolation. The variant's clinical relevance is context-dependent, not intrinsic.

Population frequency is low and strongly European-enriched: the T allele occurs at ~2.2% in Europeans and under 0.4% in African and South Asian populations, with near-absence in East Asians. This ancestry skew is consistent with a European founder haplotype.

Practical Actions

For most carriers, the variant is a monitoring signal rather than an emergency. The key practical step is baseline VWF antigen and FVIII activity measurement — this tells you whether levels are in the range where the variant is functionally relevant (typically VWF:Ag below 50 IU/dL or FVIII activity below 50%). If levels are normal, no further action is needed. If they are low-normal (50-100 IU/dL), tracking them is useful since acquired stressors (surgery, pregnancy, illness) can temporarily suppress VWF further. Carriers who also have blood group O should have this combination specifically noted, as the dual effect increases the probability that levels are measurably reduced.

Carriers contemplating surgery, tooth extraction, childbirth, or procedures involving significant bleeding risk should disclose this variant and have VWF/FVIII checked beforehand so that a hematologist can determine whether desmopressin (DDAVP) or VWF concentrate prophylaxis is warranted.

Interactions

The most clinically significant interaction is with ABO blood group O (rs505922 and related ABO loci). Blood group O reduces VWF levels 25-35% independently; the R924Q haplotype adds a further reduction, and together they account for up to 35% of VWF variance in carriers. This combination warrants specific clinical attention.

Any second pathogenic VWF variant — such as those causing type 1 or type 2 VWD — compounds with R924Q additively. In the Hickson cohort, 5 of 6 R924Q-carrying VWD cases had an additional VWF mutation, suggesting R924Q functions as a disease modifier that amplifies the effect of a primary mutation rather than a standalone cause.

Adolescent idiopathic scoliosis (AIS) affects 2–3% of the population and is characterized by a lateral curvature of the spine with no clear structural or neuromuscular cause. Most cases are mild and never require intervention, but roughly 10% of affected adolescents experience progressive curves that exceed 40–50 degrees and require bracing or surgery. The genetic factors that determine who progresses and who stabilizes have long been elusive. This variant sits at the center of one of the strongest progression-specific genetic signals yet identified.

MIR4300HG is the host gene for microRNA MIR4300¹¹ microRNA MIR4300
a small non-coding RNA whose primary role is post-transcriptional gene regulation — it binds to the 3′ UTR of target mRNAs and suppresses their translation. MIR4300HG is most highly expressed in testis, followed by spinal cord, bone, vertebral disc, and cartilage — precisely the tissues involved in scoliotic deformity.

The Mechanism

rs35333564 is a single-nucleotide indel in a homopolymeric G-run (GGG→GG) in intron 1 of MIR4300HG. Luciferase reporter and electrophoretic mobility shift assays²² Luciferase reporter and electrophoretic mobility shift assays
laboratory techniques for measuring transcriptional activity and protein-DNA binding showed that the region containing rs35333564 has enhancer activity, and that the risk allele (the intact GGG sequence, the less common allele) significantly reduces this enhancer function compared to the deletion allele. The mechanism is likely related to altered transcription factor binding — EMSA showed allele-specific differences in protein-DNA binding at this exact position.

The result is lower expression of MIR4300 in individuals carrying the risk allele. Wang et al. 2021³³ Wang et al. 2021 confirmed in 76 paraspinal muscle biopsy samples that the GGG homozygote genotype was associated with significantly reduced MIR4300 expression (p=0.020), and that MIR4300 expression levels correlated inversely with Cobb angle magnitude (p=0.010). The paper also identified CRTC1 (CREB-regulated transcription coactivator 1) as a candidate downstream target of MIR4300 regulation: CRTC1 expression was negatively correlated with MIR4300 (p=0.012) and positively correlated with curve severity (p=0.025), suggesting a pathway from reduced MIR4300 → elevated CRTC1 → progressive curvature.

The Evidence

Ogura et al. 2017 in Human Molecular Genetics⁴⁴ Ogura et al. 2017 in Human Molecular Genetics performed a GWAS specifically for AIS curve progression (not susceptibility) in 2,543 Japanese AIS subjects and identified rs35333564 as the functional variant within the associated locus. The combined odds ratio was 1.56 (95% CI 1.35–1.80) with a genome-wide significant P-value of 1.98×10⁻⁹. The association was with curve progression rather than with AIS onset, making it clinically distinct from the many susceptibility loci already in the literature.

Wang et al. 2021⁵⁵ Wang et al. 2021 replicated this finding in a Chinese cohort (1,952 AIS patients vs. 2,495 controls; 747 progressive vs. 520 non-progressive), confirming that rs35333564 was significantly associated with curve severity (p=0.025) but not with AIS development (p=0.418). This susceptibility-vs.-progression distinction is important: the variant does not increase your chance of developing AIS, but does affect how severe curves may become in those who have it.

Dai et al. 2025 in Spine⁶⁶ Dai et al. 2025 in Spine evaluated 259 female AIS patients undergoing brace treatment and found no significant association between rs35333564 and bracing outcome. This suggests the variant influences natural history of curve progression but does not predict responsiveness to mechanical correction.

The risk allele shows notable population stratification: it is approximately 5× more common in East Asian populations (~19%) than in Europeans (~4%), broadly consistent with higher AIS prevalence and progression rates observed in East Asian cohorts.

Practical Actions

For adolescents diagnosed with AIS who carry one or two copies of the risk allele, the main implication is heightened vigilance for curve progression during the growth spurt years. Orthopedic monitoring should follow the curve trajectory closely. Earlier initiation of brace therapy at lower Cobb angles may be warranted in progressive-allele carriers, since bracing is most effective before curves reach 40 degrees. Vitamin D and calcium adequacy support bone density and spinal development during adolescent growth, and deficiency of either can independently worsen scoliotic outcomes.

Currently there are no supplements or dietary interventions that directly target the MIR4300/CRTC1 pathway. Management is through orthopedic monitoring and timely intervention.

Interactions

rs1828853 is the GWAS index SNP for this locus (r²≥0.8 with rs35333564) and is also located in MIR4300HG intron 1. The two variants are in strong LD; rs35333564 is the functional variant confirmed by the molecular assays. No interactions with other scoliosis susceptibility loci (LBX1 rs11190870, GPR126 rs6570507, BNC2 rs10738445) have been directly tested for rs35333564.

The angiotensinogen gene (AGT) sits at the top of the renin-angiotensin-aldosterone system (RAAS), the body's primary hormonal axis for controlling blood pressure and fluid balance. Angiotensinogen is the sole precursor substrate for all angiotensin peptides¹¹ Angiotensinogen is the sole precursor substrate for all angiotensin peptides
renin cleaves AGT to produce angiotensin I, which ACE converts to the vasoconstrictor angiotensin II. During pregnancy, RAAS activity is tightly regulated: the system must expand blood volume to support the growing fetus while preventing excessive vasoconstriction that can compromise placental perfusion. When this balance fails, the result is gestational hypertension or preeclampsia — a condition affecting 3–5% of pregnancies and responsible for roughly 14% of maternal deaths worldwide.

The rs3889728 variant lies within an intron of AGT on chromosome 1 (GRCh38 position 230,713,085). The AGT gene runs on the minus strand, so the T allele in genome files corresponds to an A on the coding strand — the allele designation sometimes used in older papers. This variant has been incorporated into a diastolic blood pressure prediction model alongside two other SNPs (rs5193 and rs7305099) in a Han Chinese cohort study, suggesting it tags a regulatory region that modulates AGT expression or splicing in contexts relevant to blood pressure control.

The Mechanism

As an intron variant, rs3889728 does not alter the AGT protein directly. Its effect is likely mediated through a regulatory element²² regulatory element
intronic enhancers, silencers, or splice-branch-point sequences that influence how much mRNA is produced and how efficiently it is processed embedded within the intron. Elevated AGT levels (whether from coding variants or regulatory changes) increase angiotensin II production, raising vascular tone and sodium retention. In pregnancy, this has particular consequences: the maternal vascular system must dilate substantially to accommodate increased cardiac output, and any genetic factor that tips RAAS toward excess activation can impair the spiral artery remodeling that supplies the placenta.

The preeclampsia connection to AGT is well-established at the gene level. The most-studied AGT variant, M235T (rs699), encodes a threonine at position 235 that increases AGT plasma concentrations by approximately 20% in TT homozygotes compared to MM individuals. A large meta-analysis found TT homozygotes have approximately 61% higher odds of preeclampsia Lin et al. 2012, 31 studies, 2,555 cases³³ Lin et al. 2012, 31 studies, 2,555 cases
Angiotensinogen gene M235T and T174M polymorphisms and susceptibility of pre-eclampsia: a meta-analysis. Ann Hum Genet. The rs3889728 variant may influence AGT expression through a parallel intronic regulatory mechanism, making it a biologically plausible though less-studied contributor to this same pathway.

The Evidence

Direct evidence for rs3889728 specifically comes from a cross-sectional study of 965 Northern Han Chinese adults by Li et al. 2019⁴⁴ Li et al. 2019
A Prediction Model of Essential Hypertension Based on Genetic and Environmental Risk Factors in Northern Han Chinese. Int J Med Sci. The authors genotyped multiple candidate SNPs in RAAS genes and found that rs3889728, together with rs5193 and rs7305099, formed the genetic component of their best-performing diastolic blood pressure prediction model (AUC 0.817). The study does not report allele-specific odds ratios for rs3889728 in isolation, limiting the precision of individual-level risk estimates.

Broader evidence for RAAS gene variants in preeclampsia is substantial. A review of RAAS polymorphisms by Wang et al. 2023⁵⁵ Wang et al. 2023
Pertinence between risk of preeclampsia and RAAS gene polymorphisms. Pregnancy Hypertens found that AGT variants (particularly the 235T allele) and AT1R 1166C are among the most replicated genetic contributors to preeclampsia risk across diverse populations. A separate meta-analysis of 40 studies by Wang et al. 2020⁶⁶ Wang et al. 2020
Three polymorphisms of renin-angiotensin system and preeclampsia risk found AGT T704C (another intronic-region AGT variant) associated with preeclampsia in the dominant model (OR 1.33, 95% CI 1.12–1.59). The fact that multiple intronic and regulatory AGT variants show association with blood pressure outcomes makes it plausible that rs3889728 participates in the same regulatory landscape.

The T allele of rs3889728 is common globally (~25% in Europeans, ~55% in East Asians), making it a variant that tags a common haplotype rather than a rare pathogenic mutation. The evidence level is emerging: the variant is incorporated in one hypertension prediction model, sits in a gene with strong preeclampsia biology, but lacks its own dedicated preeclampsia association study or ClinVar entry.

Practical Actions

For women carrying one or two T alleles, the primary implications are during pregnancy. The RAAS context means that blood pressure monitoring during pregnancy is particularly important — early detection of gestational hypertension allows timely intervention before preeclampsia develops. Low-dose aspirin (81 mg/day from 12–16 weeks) is guideline-recommended for moderate-to-high-risk pregnancies and acts partly by improving placental perfusion and modulating RAAS-mediated vasoconstriction.

Outside pregnancy, the blood pressure relevance of rs3889728 may be modest but meaningful in the context of a RAAS genetic profile. Salt sensitivity and fluid balance are domains where RAAS gene variants cluster — higher sodium intake is associated with greater AGT pathway activation in genetically susceptible individuals.

Interactions

The most relevant interaction is with AT1R rs5186 (A1166C), the angiotensin II type 1 receptor gene variant. AGT produces angiotensin II; AT1R is where angiotensin II acts. Carrying risk alleles in both genes (elevated angiotensin II production from AGT variants and increased receptor sensitivity from AT1R 1166C) compounds the blood pressure effect and has been proposed as a particularly high-risk combination for preeclampsia in several case-control studies. See rs5186 for the AT1R profile. The NPR3 variant rs13154066 affects a complementary vasodilatory pathway (natriuretic peptide clearance); women carrying hypertension-risk alleles in both the RAAS (AGT, AT1R) and natriuretic peptide (NPR3) pathways face convergent pressure toward gestational blood pressure elevation.

Complement factor B (CFB) is the gatekeeping enzyme of the alternative complement pathway — the arm of innate immunity that amplifies inflammatory destruction against pathogens, dead cells, and, in the wrong circumstances, healthy tissue. When factor B binds to C3b¹¹ C3b
the activated form of complement component 3 that acts as an opsonin and amplification hub and forms the C3 convertase complex, it triggers a cascade that deposits inflammatory mediators, recruits immune cells, and, in the retina, damages the delicate photoreceptor support layer. The rs4151667 L9H variant sits in the signal peptide of CFB — the molecular zip code that directs the newly synthesized protein into the secretory pathway — and is one of only two protective non-synonymous variants in the CFB gene with established AMD association. Carriers of the protective A allele have approximately 50% lower odds of developing age-related macular degeneration (AMD), one of the leading causes of irreversible vision loss in adults over 65.

The Mechanism

The L9H substitution (leucine to histidine at position 9) lies within the CFB signal peptide, the short hydrophobic leader sequence encoded by exon 1 that is cleaved co-translationally as the protein enters the endoplasmic reticulum. Signal peptide variants can alter secretion efficiency, folding kinetics, or the quantity of mature protein released into circulation. The functional consequence of L9H has not been fully characterized at the molecular level²² The functional consequence of L9H has not been fully characterized at the molecular level
Gold et al. 2006 acknowledged that direct functional demonstration was lacking but proposed that L9H could modulate CFB secretion and therefore the supply of factor B available for convertase assembly. A plausible model is that the histidine substitution subtly reduces secretion efficiency, producing slightly less circulating factor B — reducing the steady-state availability of the substrate needed for C3 convertase assembly and thereby dampening basal alternative pathway tick-over.

L9H is in nearly complete linkage disequilibrium (LD) with the C2 E318D variant (rs9332739), forming the well-characterized protective haplotype H10. The co-occurrence of these two variants in cis means that the AMD protection attributed to L9H likely reflects the combined effect of reduced CFB secretion efficiency and altered C2 classical pathway activity, and it remains difficult to disentangle the independent contribution of each polymorphism. The functionally better-characterised CFB R32Q variant (rs641153)³³ CFB R32Q variant (rs641153)
a missense variant at codon 32 in the Ba domain; Q32 binds C3b with up to 4× lower affinity than R32, directly reducing C3 convertase formation is on a distinct protective haplotype (H7) in high LD with C2 rs9332739 but not with L9H, and serves as a mechanistic model for how reduced CFB activity protects the complement-vulnerable retinal pigment epithelium.

The Evidence

The initial discovery of CFB L9H as an AMD protective variant came from a 2006 landmark Nature Genetics study by Gold et al.⁴⁴ Nature Genetics study by Gold et al.
Two independent cohorts totalling ~900 AMD cases and ~400 controls; protective haplotype H10 carrying L9H had OR 0.36; standalone L9H had OR 0.45 per allele; combined with CFH variation, 74% of clinical outcomes were explained. Multiple subsequent meta-analyses confirmed the protection. A 2012 HuGE review and meta-analysis by Thakkinstian et al.⁵⁵ 2012 HuGE review and meta-analysis by Thakkinstian et al.
Pooled 19 studies, 2006–2011; rs4151667 A allele OR 0.54 (95% CI 0.45–0.64); absolute AMD risk reduction of 2–6% in Caucasians synthesised the population-level effect. A concurrent Sun et al. systematic review and meta-analysis⁶⁶ Sun et al. systematic review and meta-analysis
15 case-control studies; dominant model pooled OR 0.496 (95% CI 0.390–0.632, P<0.001) in Caucasians; protective effect weaker in Asians (AT/TT OR 0.68) corroborated the finding.

The protective effect is population-dependent: it is most consistently replicated in Europeans, where the A allele frequency is approximately 4–7%, while a negative case-control study in an Iranian cohort (n=407) found no significant association, likely reflecting differences in local LD patterns and haplotype backgrounds. The protective haplotype H10 (L9H + C2 E318D) contributes a 2–6% absolute risk reduction in Caucasian populations — modest in isolation, but large relative effects when AMD baseline risk is stratified by concomitant CFH risk genotype.

Functionally, the best evidence for the mechanism comes from the Heurich et al. 2011 PNAS complotype study⁷⁷ Heurich et al. 2011 PNAS complotype study
showed the full complement of common CFB, C3, and CFH polymorphisms can span a 6-fold range in hemolytic complement activity; the R32Q variant (in LD with the L9H haplotype background) reduces C3b binding affinity up to 4-fold, substantially lowering complement amplification.

Practical Actions

The protective A allele acts as a dampener on the alternative complement pathway. For heterozygous AT carriers, one copy reduces complement-driven drusen formation risk by approximately 40–50% per the population data. Homozygous AA carriers (rare, ~0.2% of Europeans) carry both copies of the protective allele and have the lowest complement-driven AMD risk from this locus.

While no supplement directly substitutes for this genetic protection, several complement pathway nutrients and lifestyle factors modulate AMD risk through overlapping pathways. The AREDS2 clinical trial formula (lutein/zeaxanthin + vitamin C + vitamin E + zinc/copper) is the only nutritional intervention with established AMD risk reduction in high-risk individuals, but its benefit is independent of CFB genotype. For AT and AA carriers, the primary actionable value lies in understanding their reduced genetic AMD risk — a meaningful counterweight to modifiable risk factors like smoking and UV exposure — while still maintaining standard AMD surveillance.

Interactions

rs4151667 is in near-complete LD with the C2 E318D variant (rs9332739), forming the H10 protective haplotype. Individuals carrying the rs4151667 A allele almost always also carry the rs9332739 C allele; the combined AMD protective effect is OR ~0.36 for the full H10 haplotype, stronger than either variant alone. The CFB R32Q variant (rs641153) provides AMD protection through a different mechanism (direct reduction in C3b binding affinity) on the independent H7 haplotype; carriers of both L9H and R32Q are exceptionally rare but would theoretically carry additive complement-dampening effects.

The L9H protective effect is most clinically relevant when assessed in the context of CFH Y402H (rs1061170) and ARMS2/HTRA1 variants — the dominant AMD risk loci. Carriers of the CFH 402H risk allele with CFB L9H protection represent a mixed-risk genetic profile where the classical-pathway (CFH) risk and alternative-pathway (CFB) protection partially offset each other. Formal risk score modelling incorporating CFH, ARMS2, and CFB variants explains the majority of AMD genetic risk in European populations.

Primary open-angle glaucoma (POAG) is the leading cause of irreversible blindness worldwide, affecting over 70 million people¹¹ affecting over 70 million people
Glaucoma is a chronic degenerative optic neuropathy with progressive loss of retinal ganglion cells resulting in characteristic optic nerve cupping and visual field defects. The disease typically progresses silently for years before vision loss becomes noticeable. The rs4236601 variant sits in the regulatory region between the CAV1 and CAV2 genes on chromosome 7q31, and was the first common genetic risk factor identified for POAG through genome-wide association studies²² was the first common genetic risk factor identified for POAG through genome-wide association studies.

The Mechanism

This intergenic variant affects the expression and function of caveolin-1 and caveolin-2, structural proteins that form caveolae — specialized flask-shaped invaginations of the plasma membrane that are abundant in the trabecular meshwork and Schlemm's canal³³ caveolae — specialized flask-shaped invaginations of the plasma membrane that are abundant in the trabecular meshwork and Schlemm's canal
These structures regulate aqueous humor outflow, the drainage system that controls intraocular pressure. The trabecular meshwork is the primary site of resistance to aqueous humor outflow, and dysfunction in this tissue is the hallmark of POAG pathophysiology.

Studies in caveolin-1 knockout mice reveal the functional importance of this protein: Cav-1-deficient mice display ocular hypertension explained by reduced pressure-dependent drainage of aqueous humor⁴⁴ Cav-1-deficient mice display ocular hypertension explained by reduced pressure-dependent drainage of aqueous humor. The loss of caveolae in the trabecular meshwork and Schlemm's canal renders these tissues unable to properly respond to mechanical stress from IOP fluctuations⁵⁵ renders these tissues unable to properly respond to mechanical stress from IOP fluctuations, suggesting that caveolae provide both mechanical buffering and mechanotransduction signaling platforms.

The rs4236601 risk variant may reduce CAV1 expression in relevant ocular tissues. While no correlation was found between rs4236601 and CAV1 expression in blood or adipose tissue⁶⁶ no correlation was found between rs4236601 and CAV1 expression in blood or adipose tissue, gene regulation is highly tissue-specific, and the variant likely affects expression specifically in the trabecular meshwork where it matters most. Some glaucoma-associated CAV1/CAV2 polymorphisms have been shown to reduce caveolin-1 expression in various tissues⁷⁷ reduce caveolin-1 expression in various tissues, supporting the hypothesis that reduced caveolae formation compromises aqueous outflow regulation.

The Evidence

The initial genome-wide association study in 1,263 Icelandic POAG cases and 34,877 controls identified rs4236601[A] with an odds ratio of 1.36 (P = 5.0 × 10⁻¹⁰)⁸⁸ genome-wide association study in 1,263 Icelandic POAG cases and 34,877 controls identified rs4236601[A] with an odds ratio of 1.36 (P = 5.0 × 10⁻¹⁰). The association was replicated in 2,175 European cases (combined OR = 1.18) and 299 Chinese cases (combined OR = 5.42)⁹⁹ replicated in 2,175 European cases (combined OR = 1.18) and 299 Chinese cases (combined OR = 5.42), demonstrating both reproducibility and striking ancestry-specific effect sizes.

The variant shows dramatic frequency differences across populations. In European populations, the A risk allele occurs at 27-29% frequency¹⁰¹⁰ 27-29% frequency, while in Chinese populations it is rare at 0.43-1.3% frequency¹¹¹¹ 0.43-1.3% frequency but carries a much larger effect size (OR = 5.26). This pattern suggests the A allele may be tagging different causal variants in different ancestral backgrounds, or that genetic background modifies penetrance.

Importantly, rs4236601 is also associated with elevated intraocular pressure (IOP) independent of glaucoma diagnosis. The minor allele A is associated with a 0.42 mm Hg increase in mean IOP¹²¹² The minor allele A is associated with a 0.42 mm Hg increase in mean IOP in European populations, and meta-analysis across multiple IOP GWAS studies achieved genome-wide significance (P = 4.0 × 10⁻¹¹)¹³¹³ meta-analysis across multiple IOP GWAS studies achieved genome-wide significance (P = 4.0 × 10⁻¹¹).

Replication studies have yielded mixed results across populations. While US Caucasian studies confirmed the association¹⁴¹⁴ US Caucasian studies confirmed the association, particularly in women, studies in Saudi Arabian¹⁵¹⁵ Saudi Arabian and Brazilian¹⁶¹⁶ Brazilian populations failed to replicate the finding. This heterogeneity may reflect differences in genetic background, linkage disequilibrium patterns, environmental factors, or POAG subtype distributions.

Practical Implications

Elevated IOP is the most important modifiable risk factor for glaucoma progression, and the only treatment target for which we have effective interventions. While rs4236601 genotype is not currently used in clinical decision-making, understanding your genetic risk can inform screening strategies and motivate adherence to regular comprehensive eye examinations.

The American Academy of Ophthalmology recommends comprehensive eye examinations for all adults over age 40¹⁷¹⁷ comprehensive eye examinations for all adults over age 40 to screen for glaucoma. Individuals with the AA genotype, particularly those with additional risk factors (family history, African ancestry, myopia, thin central corneal thickness), may benefit from more frequent screening and earlier initiation of monitoring protocols.

IOP exhibits substantial diurnal variation, with many glaucoma patients experiencing peak pressures in the early morning hours outside of office visit times¹⁸¹⁸ peak pressures in the early morning hours outside of office visit times. Home tonometry devices now enable continuous monitoring that may detect pressure spikes missed by clinic measurements, potentially enabling more personalized treatment approaches.

Interactions

The CAV1/CAV2 locus interacts functionally with the nitric oxide signaling pathway, as caveolin-1 regulates endothelial nitric oxide synthase (eNOS) activity in caveolae. This connection may explain the association between CAV1/CAV2 variants and POAG subtypes characterized by vascular dysregulation¹⁹¹⁹ association between CAV1/CAV2 variants and POAG subtypes characterized by vascular dysregulation, particularly normal-tension glaucoma and cases with paracentral visual field defects. The interaction between ET-1 (endothelin-1), NO, and CAV1 is suspected to underlie aberrant retinal hemodynamic responses to postural changes observed in POAG patients.

Other POAG risk loci include CDKN2B-AS1 (rs2157719), TMCO1 (rs7518099), and SIX1/SIX6 (rs10483727). While no specific gene-gene interactions between rs4236601 and these loci have been definitively established, polygenic risk scores incorporating multiple POAG variants show additive effects on disease risk.

Your kidneys filter roughly 700 mg of uric acid every day and then reabsorb most of it — resetting your blood urate baseline with each filtration cycle. The protein that handles the largest share of that reabsorption is GLUT9¹¹ GLUT9
Glucose Transporter 9, encoded by SLC2A9. Despite its name, GLUT9's dominant physiological role in the adult kidney is voltage-driven urate transport, not glucose, encoded by the SLC2A9 gene on chromosome 4. rs4519796 sits 292 base pairs upstream of a well-characterised intronic SLC2A9 risk variant (rs6814664), in the same intronic region of the gene, and carries an identical population-frequency signature: the A allele is most common in East Asians (~92%), who have the world's highest rates of gout, and least common in Africans (~34%), who historically have had lower gout burden. This gradient is the hallmark of SLC2A9 urate-reabsorption risk haplotypes.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the circulation, and GLUT9b on the apical membrane, which accepts urate from the tubular lumen. Together they form the dominant urate-recapture system: filtered urate enters the lumen, URAT1 shuttles it into the tubular cell, and GLUT9a pumps it back into blood. Variants in the intronic and regulatory regions of SLC2A9 modulate how much GLUT9 is expressed, rather than changing the protein's sequence. Fine-mapping of the SLC2A9 locus²² Fine-mapping of the SLC2A9 locus
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 has identified multiple independent signals with epistatic interactions, collectively explaining more urate variance than any single SNP. rs4519796 is positioned within this same regulatory window and is a likely tag for haplotypes that increase GLUT9 expression or transport activity, resulting in more urate being retained per filtration cycle.

Because no published study has directly tested rs4519796 in isolation, the evidence for this specific variant rests on its position within the SLC2A9 risk locus and its population frequency gradient — not on a direct genotype-phenotype association study. This places rs4519796 in the emerging evidence tier: the locus effect is established, but this variant's independent contribution has not been formally quantified.

The Evidence

The SLC2A9 locus is the most replicated genetic determinant of serum urate in humans. Vitart et al. (2008)³³ Vitart et al. (2008)
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 showed that intronic SLC2A9 variants explain 1.7–5.3% of serum urate variance across Croatian, UK, and German samples and associate with reduced fractional excretion of uric acid — confirming that the mechanism is impaired renal clearance, not overproduction.

Döring et al. (2008)⁴⁴ Döring et al. (2008)
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 found that SLC2A9 intronic variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men and a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele, with women showing up to twice the effect size of men. SLC2A9 isoform 2 expression explained 3.5% of urate variance in men and 15% in women — likely reflecting estrogen-mediated regulation of GLUT9 in proximal tubule cells.

Across the SLC2A9 locus as a whole, Yang et al. (2010)⁵⁵ Yang et al. (2010)
Yang Q et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet, 2010 confirmed that SLC2A9 and ABCG2 are the only two loci reaching genome-wide significance for gout across 28,283 participants in a multi-cohort meta-analysis, underscoring the transporter axis as the dominant genetic driver of gout susceptibility.

Sex-specific note: The sex-divergent effect of SLC2A9 intronic variants is one of the best-replicated gene-by-sex interactions in metabolic genetics. Women carrying the risk haplotype — who have lower baseline urate than men and therefore face a proportionally larger relative increase — should treat this variant's significance as equivalent to, or greater than, the warning level applied to men with the same genotype.

Practical Actions

The actionable levers for A-allele carriers mirror those for adjacent SLC2A9 variants: reduce the urate substrate that the overactive GLUT9 transporter is positioned to recapture. Organ meats (liver, kidney, sweetbreads) and red meat are the highest-purine dietary sources. Alcohol — especially beer, which combines brewer's yeast purines with ethanol's direct urate-retention effect — is the most potent modifiable trigger. High-fructose intake drives urate synthesis through inosine monophosphate generation and competes with urate for SLC2A9 transport. Low-fat dairy and coffee are associated with lower serum urate in epidemiological data.

The clinical urate crystallisation threshold is 6.8 mg/dL; maintaining serum urate below 6.0 mg/dL is the standard prevention target.

Interactions

With rs6814664 (SLC2A9 intronic, 292 bp downstream): rs6814664 is the nearest characterised SLC2A9 intronic risk variant (C allele = risk) and the two SNPs share the same population frequency gradient. Individuals carrying both A at rs4519796 and C at rs6814664 carry the full SLC2A9 intronic risk haplotype in this region of the gene.

With rs3733591 (SLC2A9 Arg265His missense): rs3733591 is an independent coding variant at SLC2A9 with larger per-allele urate effect (~0.65 mg/dL). A carriers at rs4519796 who also carry C at rs3733591 face additive urate burden from both regulatory and protein-level mechanisms.

With rs2231142 (ABCG2 Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. A-allele carriers at rs4519796 who also carry the ABCG2 Q141K T allele face elevated urate from two mechanistically independent routes, substantially compounding gout risk.

With BMI: SLC2A9 intronic variant effects on serum urate are amplified at higher BMI — a replicated interaction in two independent cohorts. AA homozygotes who are overweight or obese accumulate a greater urate load than the genotype alone predicts; weight reduction has proportionally greater benefit in this group.